# A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis

> **NCT06293053** · PHASE3 · RECRUITING · sponsor: **Sanofi** · enrollment: 18 (estimated)

## Conditions studied

- Prurigo Nodularis

## Interventions

- **DRUG:** Dupilumab

## Key facts

- **NCT ID:** NCT06293053
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-15
- **Primary completion:** 2027-10-28
- **Final completion:** 2027-11-03
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06293053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06293053, "A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06293053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*